|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
1/24/2013 7:03:51 AM
AbbVie Inc (ABBV.N), the new branded pharmaceuticals company spun off by Abbott Laboratories Inc (ABT.N), is off to a good start, judging by fourth-quarter sales of arthritis drug Humira and other products in its medicine chest. The picture, although healthy, could be more challenging for the remaining Abbott, nicknamed "new Abbott," which continues to sell medical devices, diagnostics, nutritional products and generic drugs, said analysts. The new Abbott said it expects earnings for 2013, excluding special items, of $1.98 to $2.04 per share, in line with its earlier guidance and above the average Wall Street forecast of $1.95. Although the company has not yet provided complete earnings data for full-year 2012, it said the mid-point of its 2013 profit forecast would likely represent double-digit earnings growth. But Abbott is still analyzing its numbers because of the split and may eventually restate some figures, analysts said. A big worry, according to Leerink Swann analyst Danielle Antalffy, is whether Abbott can revive sales of its branded generic medicines, which the company calls established pharmaceuticals. Sales of the products slipped 4 percent in 2012 to $5.1 billion. Abbott predicted they would capture mid-single-digit growth this year, excluding the impact of foreign exchange rates. "The business, which represents 25 percent of company sales, has been underperforming," Antalffy said, adding that revenue forecasts for the business are difficult because they rely on data from so many local markets and countries.
|
|
|
|
|
|
|
|
|
|
|